Glioblastoma Multiforme Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||922031|
|出版日期||內容資訊||英文 112 Pages
|全球多形性膠質母細胞瘤( 神經膠質母細胞瘤，GBM)治療市場:成長，趨勢，及預測 Glioblastoma Multiforme Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 112 Pages||
A brain tumor occurs when abnormal cells form as well as grow within a brain. Factors such as the increasing burden of brain disorders, strong R&D initiatives from key players and rising geriatric population are boosting the growth of the glioblastoma multiforme treatment market. As per the estimates of Globocan 2018, the number of new cases of brain cancer across the world was 296,851 in 2018. This leads to increased care providers shifting to the mainstream treatment associated with the glioblastoma treatment. Hence, the growing focus toward the development of better treatment options invites more cancer chemotherapy based companies to generate innovative drugs as well as explore different geographic regions to grow the sales of chemotherapy and radiation therapy products thus fueling the growth of glioblastoma multiforme treatment market.
However, low approval rates for novel therapies, reimbursement issues, and stringent regulatory guidelines are expected to restrain the growth of the global market in the forecast period.
As per the scope of the report, Glioblastoma Multiforme (GBM), also known as glioblastoma, is the most common type of malignant brain tumor. Brain tumor arises from abnormal growth of cancerous cells in the brain. The brain tumor is one of the leading causes of death, globally.
Chemotherapy Segment is Expected to Dominate the Market
Based on treatment, the market is segmented into chemotherapy, radiation therapy, and others. The chemotherapy segment is expected to dominate the market. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing generic products for the treatment of neurological diseases like brain stroke; as well as glioblastoma in order to maintain their competitive advantage and penetrate new regional markets across the developed and emerging markets. In addition, the pipeline of glioblastoma multiforme is rich with the number of drugs that are expected to receive FDA approval steadily over the period. Also, an increase in funding for companies involved in the research related to glioblastoma is expected to boost the interest of venture partner companies, investors and new mergers as well as acquisition-related to this segment of the studied market.
North America leads the Glioblastoma Multiforme Treatment Market
North America leads the glioblastoma multiforme treatment market, owing to a rise in funding initiatives and awareness among patients, followed by Europe. According to the American Society of Clinical Oncology (ASCO), in 2019, it is expected that an estimated 23,820 adults (13,410 men and 10,410 women) in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord. Brain tumors account for 85% to 90% of all primary CNS tumors. However, Asia Pacific is expected to grow at a faster rate due to the increasing awareness regarding advanced treatment options, and the presence of emerging economies in this region.
The leading players in the global glioblastoma multiforme treatment market are - Arbor Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sun Pharmaceutical and Teva Pharmaceutical Industries Ltd.